Bolt Biotherapeutics vs Kyntra BIO
Bolt Biotherapeutics is the larger business, with $7.7m of revenue in fiscal 2025 against $6.4m for Kyntra BIO (1.2 times as much). Bolt Biotherapeutics grew faster (0.1% against -78.3%). Kyntra BIO kept more of each dollar of sales as profit: a net margin of 2848.6% against -433.7%.
| Latest fiscal year | Bolt BiotherapeuticsBOLT, 2025 | Kyntra BIOKYNB, 2025 |
|---|---|---|
| Revenue | $7.7m | $6.4m |
| Revenue growth | 0.1% | -78.3% |
| Net income | −$33.4m | $183m |
| Operating margin | -469.3% | -712.7% |
| Net margin | -433.7% | 2848.6% |
| Return on equity | -79.7% | — |
| Free cash flow | −$39.9m | −$4.8m |
| Cash | $11.7m | $47.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 34 |
| Market value | $12.7m | $17.5m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 4 buys, 9 sales | 4 buys, 0 sales |